Cibi e Bevande
Peanut Allergy Market is Set for Remarkable Growth at a 21.88% CAGR During the Study Period [2018-2030], Says DelveInsight
Peanut Allergy is a reaction that occurs when the body mistakenly identifies peanuts as harmful substances. It accounts for the majority of severe food-related allergic reactions.
DelveInsight estimates that the in 2020 were cases in 7MM, out of which the highest cases were observed in the United States .
Peanut avoidance was considered the first line of treatment for anyone at risk of developing a Peanut Allergy. However, the updated guidelines outlined that the children should be given peanuts based on their allergy risk: high-risk children (with severe eczema, egg allergy, or both) around 4–6 months, moderate-risk children (with mild-to-moderate eczema or other food allergies) around six months, and low-risk children (without eczema or food allergies) at their parent's discretion.
is the first-line medication for anaphylaxis treatment. Intramuscular (IM) or intravenous (IV) epinephrine should be administered, although the IM route is given preference, with injection placement in the lateral thigh. IV administration ideally should be administered in the inpatient setting with appropriate monitoring. may also be utilized, but it is vital to realize these medications do not treat anaphylaxis; instead, they are adjunctive therapies for anaphylaxis management. IV fluids should be administered to prevent and treat tissue hypoperfusion.
, developed by , is the first FDA-approved oral immunotherapy for Peanut Allergy treatment. It is made up of carefully selected doses of peanut powder taken by mouth and is designed for children and teens aged 4–17 with existing peanut allergies. Palforzia's purpose is to desensitize children to peanuts. It is available only through a Risk Evaluation and Mitigation Strategy (REMS).
a recombinant DNA-derived humanized IgG1 monoclonal antibody, is used as an off-label in few clinics. The drug is also evaluated as monotherapy and adjunct therapy to multi-allergen oral immunotherapy in food allergic children and adults.
in clinical development include being developed by . Other assets are . It is expected that the launch of these drugs is likely to expand the Peanut Allergy market size during the forecast period.
Peanut Allergy Market shall enlarge as oral peanut immunotherapy facilitates to with for the healthcare system and . Also, of Peanut Allergies offer opportunities to companies to launch in the market. The Peanut Allergy treatment market is expected to increase soon due to the during the past few years.
However, desensitizing patients to their allergens with oral immunotherapy takes from 6 months to 1 year and can
along the way. Even with strict avoidance, accidental exposures can occur in allergic individuals, leading to
. Also, there is to explain the rise of disease. There has been
between oral Immunotherapy trials with different dosing regimens and endpoints, making results . In addition to that, the anticipated
raises issues for payers regarding how they will integrate these novel therapies into formularies and treatment continuums.
DelveInsight's Peanut Allergy - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Peanut Allergy in the 7MM.
Peanut Allergy - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 " report by DelveInsight offers comprehensive insights on marketed and Phase III products for Peanut Allergy.
Peanut Allergy Pipeline Insights, 2021 report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Peanut Allergy market. Key companies such as and others are developing therapies.
DelveInsight's House Dust Mite Allergy- Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology.
DelveInsight's Allergic Bronchopulmonary Aspergillosis - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg